Flu vaccine offers moderate protection against strains dominant in most European countries in 2024/2025
._Credit-_NIAID_(31028518766).png){kind=link}
According to interim analysis of influenza vaccine effectiveness for the 2024/2025 season in Europe, the vaccine offered moderate protection against dominant influenza A strains, and strong protection against influenza B.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.